Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. Residual cardiovascular (CV) risk persists among high-risk patients despite achievement of target LDL-C levels. In addition to elevated LDL-C, low HDL-C has been found in epidemiological studies to independently predict coronary heart disease (CHD) risk.

HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-1291. Residual risk for cardiovascular disease is seen among many high-risk patients despite LDL-C lowering with statins, and controlling blood pressure and diabetes. Niacin (nicotinic acid) is commonly prescribed as an add-on to statin therapy for incremental lowering of LDL-C, apoB, Lp(a), and triglycerides (TG); and incremental increasing of HDL-C and apoA1.

Patient education handout exploring appropriate triglyceride levels and targets—in Spanish.

Patient education handout exploring appropriate triglyceride levels and targets.

Patient education handout exploring appropriate cholesterol levels and targets—in Spanish.

Patient education handout exploring appropriate cholesterol levels and targets.

Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high residual risk of vascular events.